XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.19

-0.79%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.19

-0.79%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.19

-0.79%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.19

-0.79%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.19

-0.79%↓

COPNY

127.33

+0.39%↑

Search

Martin Midstream Partners LP

Gesloten

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

5.5M

-2.9M

Verkoop

5.5M

174M

EPS

-0.072

Dividendrendement

0.72

Winstmarge

-1.661

EBITDA

5.6M

25M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+32.16% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.72%

3.56%

Volgende Winsten

15 apr 2026

Volgende dividenddatum

14 mei 2026

Volgende Ex Dividend datum

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.7M

105M

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Martin Midstream Partners LP Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Martin Midstream Partners LP Prognose

Koersdoel

By TipRanks

32.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3 USD  32.16%

Hoogste 3 USD

Laagste 3 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Martin Midstream Partners LP - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Technische score

By Trading Central

2.77 / 3.14Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Very Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Martin Midstream Partners LP

Martin Midstream Partners L.P., together with its subsidiaries, provides terminalling, processing, storage, and packaging services for petroleum products and by-products primarily in the United States. The company operates in four segments: Terminalling and Storage, Transportation, Sulfur Services, and Specialty Products. The company's Terminalling and Storage segment owns or operates various marine shore-based terminal facilities and specialty terminal facilities that provide storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products. This segment also offers land rental services to oil and gas companies, as well as storage and handling services for lubricants and fuels. Its Transportation segment operates various trucks and tank trailers; and inland marine tank barges, inland push boats, and articulated offshore tug and barge unit to transport petroleum products and by-products, petrochemicals, and chemicals. The company's Sulfur Services segment processes molten sulfur into prilled or pelletized sulfur, which is used in the production of fertilizers and industrial chemicals. Its Specialty Products segment stores, distributes, and transports natural gas liquids for wholesale deliveries to refineries, industrial natural gas liquid users, and propane retailers. Martin Midstream GP LLC serves as a general partner of the company. Martin Midstream Partners L.P. was incorporated in 2002 and is based in Kilgore, Texas.
help-icon Live chat